{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:13:07Z","timestamp":1763748787546,"version":"3.40.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are no enough evidences to show it effectiveness for all patients with SARS-COV-2, especially among elderly patients and newest Omicron variant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnosis:<\/jats:title>\n            <jats:p>A 79 year\u2019s old female patient was admitted to hospital because of the moderate COVID-19 caused by the Omicron variant BA2.0. He presented the initial syndromes including Xerostomia, cough and fever. Chest computed tomography (CT) scanning at admission showed the exudation lesions on lung. The laboratory examination revealed that there are increased C-reactive protein (CRP), Ferritin and erythrocytesedimentationrate (ESR) and decreased white blood cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The oral Paxlovid (Nirmatrelvir\/Ritonavir) was administrated on second day after admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The syndromes of Xerostomia, cough and fever was improved on third day after use of Paxlovid. The levels of CRP, ESR and counts of white blood cells returned the normal after three days of admission. The chest CT scanned on the third and sixth day after Paxlovid used showed the absorption of lesions. The examination of SARS-COVS viral nucleic acid turned negative at fifth day of admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>As a result, we would consider that Paxlovid is a suitable oral drug for elderly patients with SARS-COV2 even Omicron variant, it\u2019s benefit to improve patient\u2019s symptom and signs and can prevents COVID-19 with the high-risk factors from severe disease, although it didn\u2019t shorten the time for viral nucleic acid to turn negative.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031361","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:08:03Z","timestamp":1668694083000},"page":"e31361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Liulu","family":"Zhang","sequence":"first","affiliation":[{"name":"Infectious Departments, Guizhou Provincial People\u2019s Hospital, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guizhou Provincial People\u2019s Hospital, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yile","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Guizhou Provincial People\u2019s Hospital, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hourong","family":"Zhou","sequence":"additional","affiliation":[{"name":"General medicine, Guizhou Provincial People\u2019s Hospital, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-9773","authenticated-orcid":false,"given":"Jianquan","family":"Li","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Guizhou Provincial People\u2019s Hospital, Guizhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(22)00372-5","article-title":"The global COVID-19 treatment divide","volume":"399","author":"Usher","year":"2022","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/v14030573","article-title":"COVID-19 at a glance: an up-to-date overview on variants, drug design and therapies","volume":"14","author":"Iacopetta","year":"2022","journal-title":"Viruses"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","article-title":"How bad is Omicron? What scientists know so far","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12041-021-01262-w","article-title":"Contributions of human ACE2 and TMPRSS2 in determining host\u2013pathogen interaction of COVID-19","volume":"100","author":"Senapati","year":"2021","journal-title":"J Genet"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral Nirmatrelvir\/Ritonavir therapy for COVID-19: the dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"173890","DOI":"10.1016\/j.ejphar.2021.173890","article-title":"A review of potential suggested drugs for coronavirus disease (COVID-19) treatment","volume":"895","author":"Tarighi","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/joim.13478","article-title":"Advances in the Omicron variant development","volume":"292","author":"Vitiello","year":"2022","journal-title":"J Intern Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.15585\/mmwr.mm7106e2","article-title":"Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant predominance \u2013 One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022","volume":"71","author":"Modes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"R12-20250504","first-page":"96","article-title":"Impact of COVID-19 on the Gut: a review of the manifestations, pathology, management, and challenges","volume":"53","author":"Suryana","year":"2021","journal-title":"Acta Med Indones"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s41556-021-00796-6","article-title":"A single-cell transcriptomic landscape of the lungs of patients with COVID-19","volume":"23","author":"Wang","year":"2021","journal-title":"Nat Cell Biol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e0250708","DOI":"10.1371\/journal.pone.0250708","article-title":"Pathological findings in organs and tissues of patients with COVID-19: a systematic review","volume":"16","author":"Peiris","year":"2021","journal-title":"PLoS One"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fpubh.2020.00383","article-title":"COVID-19: a multidisciplinary review","volume":"8","author":"Chams","year":"2020","journal-title":"Front Public Health"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: vulnerability, immunity and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cells10020206","article-title":"COVID-19: characteristics and therapeutics","volume":"10","author":"Chilamakuri","year":"2021","journal-title":"Cells"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:03:22Z","timestamp":1746335002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":17,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031361","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}